Deregulated expression and/or activity of Protein Tyrosine Kinases (PTKs) and their downstream signaling proteins are now widely recognized as oncogenesis-driving mechanisms that are amenable to targeted therapies. Studies by the PI and others have established the Cbl family of ubiquitin ligases (E3s) as physiological negative regulators of PTK signaling. Cbl proteins interact with PTKs and their effectors to promote their ubiquitination resulting in degradation-dependent or degradation-independent negative regulation of PTK signaling. Consistent with the importance of this mechanism in PTK regulation, mutations of Cbl that cluster in regions (linker region and RING finger) essential for E3 activity have now been identified in a subset of patients with myeloproliferative neoplasms and leukemia. Notably, most patients show acquired Uniparental Disomy with mutant Cbl allele replacing the wildtype allele. These findings lead us to our working hypotheses that Cbl is a tumor suppressor and that mutant Cbl proteins attain transforming properties due dominant-negative inhibition of endogenous Cbl proteins together with a gain-of-function trait that is selected for in cancer. Based on biochemical studies in previous funding cycles of this grant and work by others, we hypothesize the following molecular mechanisms for oncogenesis by Cbl mutants: The E3-deficient Cbl mutants produce dominant-negative inhibition of Cbl and related Cbl-b by competing for binding to activated target PTKs. Mutant Cbl proteins also serve as supra- molecular scaffolds to juxtapose the associated hyperactive PTKs with mutant Cbl-bound signaling intermediates to create a gain of function oncogenic cascade. This combination of dominant-negative and GOF mechanisms is hypothesized to allow the mutant Cbl proteins to establish a PTK-dependent oncogenic signaling cascade. In this renewal application, we will leverage our vast expertise and unique resources to test this model using molecular, biochemical, cellular and animal-based analyses. We will use engineer oncogenic Cbl mutant proteins that cannot interact with upstream PTKs through the TKB domain or with other signaling effectors through their C-terminal regions. In vitro and in vivo oncogenesis studies of these engineered proteins in hematopoietic stem/progenitor cells derived from wildtype, Cbl-null, Cbl-b-null and Cbl/Cbl-b-null backgrounds (which are available) will help test the role of key structural domains of mutant Cbl in establishing dominant-negative and gain-of-function mechanisms to drive oncogenesis. The engineered mutants and hematopoietic stem/progenitor cells expressing these, together with cells from an available Cbl RING Finger Knock-In mouse model, will be used to identify PTK and signaling protein partners that are required for mutant Cbl oncogenesis. Multi-pronged overexpression, knock-down/knockout, dominant-negative protein expression and chemical inhibition approaches will validate the role of identified Cbl partners in oncogenesis. Successful accomplishment of the proposed goals will help bring together the conceptual frameworks established during the previous cycles of this grant together with recent advances in the field to elucidate the mechanisms by which Cbl mutations contribute to human cancer and provide a conceptual and experimental framework for novel options towards targeted therapy of patients with Cbl mutations and related malignancies.

Public Health Relevance

Loss of genes that suppress the tendency of normal cells to become cancerous (tumor supressor genes) and mutation of genes that lead to the formation of oncogenes serve as drivers of human cancer. Our laboratory studies a group of proteins, the Cbl protein family, that control the levels and activity of receptors on normal cells that help our cells receive and process external signals, and they function as molecular brakes. Recent studies have identified loss of normal Cbl and accumulation of mutant Cbl protein in a subset of human leukemias, indicating that normal Cbl functions as a tumor suppressor and the mutant version as an oncogene. Based on our prior and ongoing molecular, cellular and animal studies, further studies are proposed to decipher the exact molecular mechanisms of cancer induced by mutations of Cbl proteins. The lessons learned here are hoped to open avenues for designing new drugs to treat human cancers in which Cbl mutants serve as drivers of cancer. The insights generated here could also help understand mechanisms of oncogenesis in other prevalent cancers in which protein tyrosine kinases (which are targeted by Cbl proteins) are deregulated.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Hildesheim, Jeffrey
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Nebraska Medical Center
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Ahmad, Gulzar; Mohapatra, Bhopal C; Schulte, Nancy A et al. (2014) Cbl-family ubiquitin ligases and their recruitment of CIN85 are largely dispensable for epidermal growth factor receptor endocytosis. Int J Biochem Cell Biol 57:123-34
Senanayake, Thulani H; Lu, Yaman; Bohling, Anna et al. (2014) Encapsulation of poorly soluble drugs in polymer-drug conjugates: effect of dual-drug nanoformulations on cancer therapy. Pharm Res 31:1605-15
Posey Jr, Avery D; Swanson, Kaitlin E; Alvarez, Manuel G et al. (2014) EHD1 mediates vesicle trafficking required for normal muscle growth and transverse tubule development. Dev Biol 387:179-90
Rafiq, Khadija; Kolpakov, Mikhail A; Seqqat, Rachid et al. (2014) c-Cbl inhibition improves cardiac function and survival in response to myocardial ischemia. Circulation 129:2031-43
Bailey, Tameka A; Luan, Haitao; Tom, Eric et al. (2014) A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. J Biol Chem 289:30443-58
Curran, Jerry; Makara, Michael A; Little, Sean C et al. (2014) EHD3-dependent endosome pathway regulates cardiac membrane excitability and physiology. Circ Res 115:68-78
Helikar, Tomas; Kochi, Naomi; Kowal, Bryan et al. (2013) A comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cells. PLoS One 8:e61757
Mohapatra, Bhopal; Ahmad, Gulzar; Nadeau, Scott et al. (2013) Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta 1833:122-39
Zhao, Xiangshan; Malhotra, Gautam K; Band, Hamid et al. (2012) Derivation of myoepithelial progenitor cells from bipotent mammary stem/progenitor cells. PLoS One 7:e35338
Gudmundsson, Hjalti; Curran, Jerry; Kashef, Farshid et al. (2012) Differential regulation of EHD3 in human and mammalian heart failure. J Mol Cell Cardiol 52:1183-90

Showing the most recent 10 out of 64 publications